tradmap

MDXG Mimedx Group, Inc.

$3.27 -15.81%

Data as of close

Healthcare · Surgical & Medical Instruments & Apparatus

Mimedx Group, Inc. (MDXG) is a healthcare company in the Surgical & Medical Instruments & Apparatus industry, with a market capitalization of $478 million. Shares last traded at $3.27, 59.1% below their 52-week high. Over the past year the stock is down 55.6%. Net profit margin is -6.3%, above the peer median of -6.9%. Revenue grew 20.0% year over year.

Market Cap
$478M
Shares Out
145.9M
EPS (TTM)
-$0.13
P/E (TTM)*
—
P/S Ratio
1.57
P/B Ratio
2.26
Dividend / Share
—
Dividend Yield
—
52-Week High
$8.00
52-Week Low
$3.02
Volume (venue)
167,525
Avg Vol (3m, venue)
94,622.492

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
-15.16%
1M
-28.65%
3M
-23.30%
6M
-9.41%
YTD
-51.59%
1Y
-55.62%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
21.10
SMA (50)
$4.47
SMA (200)
$4.26
Price vs SMA50
-26.67%
Price vs SMA200
-23.17%
ATR (14)
$0.24

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$304M
Net Income
-$19M
Gross Margin
77.3%
Operating Margin
-8.3%
Net Margin
-6.3%
Return on Equity
-9.1%
Return on Assets
-7.3%
Current Ratio
4.35
Debt / Equity
0.00
Revenue Growth (YoY)
+20.0%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-09-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q3 2026 -$0.06 2026-10-28
Q2 2026 -$0.10 2026-07-29
Q1 2026 -$0.07 2026-04-29
Q4 2025 (derived) $0.10 2026-02-25
FY 2025 $0.32 2026-02-25
Q3 2025 $0.11 2025-10-29

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Surgical & Medical Instruments & Apparatus peers

MDXG vs 14 industry peers (Surgical & Medical Instruments & Apparatus), by market cap. Data as of close

P/S vs peers
1.57 / 2.81 med
-44% discount
Net margin vs peers
-6.3% / -6.9% med
above median
1–14 of 14
SYKStryker Corporation$116.8B32.254.4413.8%+5.32%
MMM3M$92.2B26.073.6514.0%+2.35%
BSXBoston Scientific$64.3B18.393.0516.6%+5.62%
BDXBecton Dickinson$54.1B57.492.604.5%+0.39%
RMDResMed$32.8B20.565.7127.8%+1.35%
DXCMDexCom$31.6B31.906.1919.4%+2.99%
MDLNMedline Inc.$29.5B—1.04—+4.80%
WSTWest Pharmaceutical Services$28.4B44.468.3618.8%-1.15%
SOLVSolventum$14.4B10.061.7417.3%+4.22%
GKOSGlaukos Corp$14.1B—20.48-24.6%+0.53%
PENPenumbra Inc$12.7B80.679.0211.2%+0.42%
BAXBaxter International$12.5B—1.08-6.2%+5.47%
GMEDGlobus Medical Inc$10.7B19.923.3917.0%+1.81%
PODDInsulet Corporation$10.7B28.393.4912.3%+2.58%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.